STOCK TITAN

Inotiv Stock Price, News & Analysis

NOTV NASDAQ

Company Description

Overview of Inotiv Inc

Inotiv Inc is a comprehensive pharmaceutical development entity that specializes in delivering nonclinical and analytical drug discovery and development services. Operating across a spectrum of industries including pharmaceuticals, chemicals, and medical devices, the company is known for its integrated approach and suite of research models, laboratory instrumentation, and contract research offerings. Key industry keywords such as "nonclinical research", "drug discovery" and "analytical services" underscore its commitment to advancing scientific innovation and meeting the needs of its diverse clientele.

Core Business Segments

The company operates through two critical segments:

  • Discovery and Safety Assessment (DSA): This segment supports every stage of the drug and device development process by providing essential nonclinical research services, safety assessments and analytical testing. It plays a pivotal role in advancing small molecule drug candidates, biotherapeutics, and biomedical technologies from the discovery phase into clinical development.
  • Research Models and Services (RMS): Focused on offering a broad range of research models—from small laboratory setups to extensive large-scale systems—this segment underpins basic research and specialized studies in disease-specific areas. Researchers rely on these models to conduct in vivo studies, pharmacokinetic investigations, and various analytical evaluations essential during preclinical development.

Operational Excellence and Business Model

Inotiv Inc has crafted a reputation for operational excellence by combining state-of-the-art laboratory instrumentation with a deep understanding of regulatory requirements and client needs. The company’s business model leverages direct service offerings, integrated research solutions and advanced scientific instrumentation, such as automated in vivo sampling systems that support behavioral and biological data collection in freely-moving subjects. Its emphasis on efficiency and quality helps clients meet critical milestones in their research and development projects.

Industry Significance and Competitive Edge

Positioned within the highly competitive contract research organization space, Inotiv stands out through its strategic integration of comprehensive services and innovative technological tools. By blending its Discovery and Safety Assessment capabilities with extensive research model resources, the company offers a unique value proposition that addresses the evolving requirements of pharmaceutical and medical device research. This integration enables a streamlined approach that reduces the complexities of transitioning from basic research to clinical development, thereby minimizing delays and promoting more reliable data generation.

Expertise, Quality, and Regulatory Compliance

The company is distinguished by its robust regulatory track record and commitment to quality and compliance. Through continuous improvements in laboratory practices, facility optimizations and adherence to animal welfare standards, Inotiv demonstrates its commitment to maintaining the highest levels of scientific integrity and ethical standards. This is critical in an environment where precision and adherence to safety protocols are essential for the successful development of new therapies and medical devices.

Comprehensive Service Offerings

Inotiv Inc’s service portfolio is designed to support customers through every step in their research and development journey. From preclinical toxicology and early in vivo pharmacokinetics to bioanalysis and full-spectrum pharmaceutical analysis, the company’s services are built around enabling groundbreaking research. Furthermore, its production of innovative scientific instruments provides researchers with the necessary tools to generate high-quality and reproducible data in a fast-paced development environment.

Market Position and Client Focus

By addressing the comprehensive needs of drug discovery and development, Inotiv has carved out a significant niche in the life sciences sector. Its dual-segment approach facilitates a full-service offering that bridges the gap between early-stage discovery and later-phase preclinical research. Accepting a wide range of client requirements, from small laboratories to larger research institutions, Inotiv’s client-centric philosophy is embedded in its operational practices, ensuring that client objectives are met through scientifically rigorous, timely and cost-effective solutions.

Conclusion

In summary, Inotiv Inc is an established force in pharmaceutical research support, leveraging its nonclinical expertise and analytical capabilities to enhance the drug and device development process. Its strategic service integration, commitment to regulatory compliance and innovative approach to scientific instrumentation solidify its role as a trusted partner for clients seeking to navigate the complexities of modern drug discovery and development.

Stock Performance

$1.87
-2.60%
0.05
Last updated: April 25, 2025 at 10:34
6.43 %
Performance 1 year
$55.9M
Market Cap
33.9M
Shares outstanding

SEC Filings

No SEC filings available for Inotiv.

Financial Highlights

$490,739,000
Revenue (TTM)
-$108,885,000
Net Income (TTM)
-$4.19
Diluted EPS (TTM)
-$6,805,000
Operating Cash Flow
-22.19%
Net Profit Margin
-17.61%
Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the current stock price of Inotiv (NOTV)?

The current stock price of Inotiv (NOTV) is $1.92 as of April 24, 2025.

What is the market cap of Inotiv (NOTV)?

The market cap of Inotiv (NOTV) is approximately 55.9M.

What is the revenue (TTM) of Inotiv (NOTV) stock?

The trailing twelve months (TTM) revenue of Inotiv (NOTV) is $490,739,000.

What is the net income of Inotiv (NOTV)?

The trailing twelve months (TTM) net income of Inotiv (NOTV) is -$108,885,000.

What is the earnings per share (EPS) of Inotiv (NOTV)?

The diluted earnings per share (EPS) of Inotiv (NOTV) is -$4.19 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Inotiv (NOTV)?

The operating cash flow of Inotiv (NOTV) is -$6,805,000.

What is the profit margin of Inotiv (NOTV)?

The net profit margin of Inotiv (NOTV) is -22.19%.

What is the operating margin of Inotiv (NOTV)?

The operating profit margin of Inotiv (NOTV) is -17.61%.

What is the current ratio of Inotiv (NOTV)?

The current ratio of Inotiv (NOTV) is 1.37, indicating the company's ability to pay short-term obligations.

What is the operating income of Inotiv (NOTV)?

The operating income of Inotiv (NOTV) is -$86,406,000.

What are the core business segments of Inotiv Inc?

Inotiv Inc operates through two main segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment focuses on nonclinical and analytical services for drug development, while the RMS segment provides diverse research models for basic and specialized studies.

Which industries does Inotiv Inc serve?

Inotiv Inc serves a broad range of industries including pharmaceuticals, chemicals, and medical devices. Its services cater to both biotherapeutics and small molecule drug candidates, as well as supporting biomedical device research.

How does Inotiv differentiate itself from competitors?

Inotiv differentiates itself by integrating advanced nonclinical and analytical services with innovative laboratory instrumentation and research models. This comprehensive approach streamlines the progression from discovery to clinical development and complies with stringent regulatory standards.

What type of research models does Inotiv offer?

Inotiv offers a wide array of research models, ranging from small and large-scale models for basic research to specialized models for disease-specific studies. These models are essential for pharmacokinetic assessments, in vivo studies, and other preclinical evaluations.

What role does regulatory compliance play in Inotiv's operations?

Regulatory compliance is a cornerstone of Inotiv's operations. The company maintains a strong track record of adhering to safety standards and ethical practices, which reinforces its credibility and ensures quality in all research and developmental activities.

How does Inotiv support the drug discovery process?

Inotiv supports the drug discovery process by offering a full suite of services that include preclinical toxicology, early in vivo pharmacokinetics, bioanalysis, and comprehensive pharmaceutical analysis. This integrated support helps reduce development timelines and improves data reliability.

What technological innovations does Inotiv incorporate in its services?

The company leverages advanced technological tools such as automated in vivo sampling systems and specialized analytical equipment. These innovations enhance data collection, improve efficiency and support high-quality research outputs essential for effective drug development.